DORVILLIUS MYLÈNE,LE DOUSSAL JEAN MARC,TERME MICKAËL
申请号：
IN201637016621
公开号：
IN201637016621A
申请日:
2016.05.12
申请国别(地区):
IN
年份:
2016
代理人:
摘要：
The present invention concerns a method for increasing the therapeutic efficacy of a human immunoglobulin G class 1 (IgG1) antibody, derivative or a functional fragment thereof comprising the step of mutating the human CHly1 domain from said antibody, so as to restore the pairing between CH1 and CL domains that is typical of the other IgG subclasses, or by substituting said human CHly1 domain by the CHI domain from a human IgG2 (CHly2), IgG3 (CHly3) or IgG4 (CHly4) an antibody, or functional fragment thereof, which can be obtained by such method, wherein said antibody comprises a) a light chain comprising the following amino acid sequences: i) the Light Chain Variable Region (LCVR) specific from an antigen and ii) a human kappa (?)Constant (CL) domain and b) a heavy chain comprising the following amino acid sequences: i) the Heavy Chain Variable Region (HCVR) specific from said antigen ii) the CH2 and CH3 domains from a human IgG1 and iii) the CH1 domain from a human IgG1, which is mutated so as to restore the pairing between CH1 and CL domains that is typical of the other IgG subclasses, or substituted by a CH1 domain from a human IgG2, IgG3 or IgG4 and its use in therapy.
